Before taking Cerdelga(Elglustat)

Important safety information and potential risks.

Warnings and Considerations

CERDELGA can cause concentration-dependent increases in PR, QTc, and QRS intervals, potentially elevating the risk of cardiac arrhythmias. Its use is contraindicated with certain strong CYP2D6 and CYP3A inhibitors and in patients with specific degrees of hepatic impairment, depending on their metabolizer status. It is not recommended for patients with pre-existing cardiac conditions, long QT syndrome, or those taking Class IA or III antiarrhythmic drugs. Concomitant use with other drugs that inhibit or induce CYP2D6 and CYP3A requires careful management or avoidance.